

Pinelopi Samara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11162266/publications.pdf>

Version: 2024-02-01

23
papers

535
citations

758635

12
h-index

713013

21
g-index

23
all docs

23
docs citations

23
times ranked

1006
citing authors

#	ARTICLE	IF	CITATIONS
1	Harnessing the immune system to improve cancer therapy. <i>Annals of Translational Medicine</i> , 2016, 4, 261-261.	0.7	225
2	Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 599-614.	2.0	39
3	Selective cytotoxicity of the herbal substance acteoside against tumor cells and its mechanistic insights. <i>Redox Biology</i> , 2018, 16, 169-178.	3.9	37
4	Polar Constituents of <i>Marrubium thessalum</i> Boiss. & Heldr. (Lamiaceae) and their Cytotoxic/Cytostatic Activity. <i>Phytotherapy Research</i> , 2012, 26, 1800-1806.	2.8	30
5	New semi-synthetic analogs of oleuropein show improved anticancer activity <i>in vitro</i> and <i>in vivo</i> . <i>European Journal of Medicinal Chemistry</i> , 2017, 137, 11-29.	2.6	27
6	Prothymosin Alpha: An Alarmin and More.... <i>Current Medicinal Chemistry</i> , 2017, 24, 1747-1760.	1.2	25
7	Expression of miR-208b and miR-499 in Greek Patients with Acute Myocardial Infarction. <i>In Vivo</i> , 2018, 32, 313-318.	0.6	24
8	Prothymosin $\hat{\pm}$ and a prothymosin $\hat{\pm}$ -derived peptide enhance TH1-type immune responses against defined HER-2/neu epitopes. <i>BMC Immunology</i> , 2013, 14, 43.	0.9	22
9	Specific <i>in vitro</i> binding of a new ^{99m} Tc-radiolabeled derivative of the C-terminal decapeptide of prothymosin alpha on human neutrophils. <i>International Journal of Pharmaceutics</i> , 2015, 486, 1-12.	2.6	18
10	The C-terminal decapeptide of prothymosin $\hat{\pm}$ is responsible for its stimulatory effect on the functions of human neutrophils <i>in vitro</i> . <i>International Immunopharmacology</i> , 2013, 15, 50-57.	1.7	16
11	Antiproliferative Activity of (-)-Rabdosiin Isolated from <i>Ocimum sanctum</i> L.. <i>Medicines (Basel)</i> , 2017, 6, 15.	0.7	15
12	miRNA polymorphisms and risk of premature coronary artery disease. <i>Hellenic Journal of Cardiology</i> , 2021, 62, 278-284.	0.4	15
13	Development of an ELISA for the quantification of the C-terminal decapeptide prothymosin $\hat{\pm}$ (100 $\hat{\pm}$ 109) in sera of mice infected with bacteria. <i>Journal of Immunological Methods</i> , 2013, 395, 54-62.	0.6	10
14	Antitumor Reactive T-Cell Responses Are Enhanced <i>In Vivo</i> by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide. <i>Cancers</i> , 2019, 11, 1764.	1.7	10
15	A flow cytometric approach for studying alterations in the cytoplasmic concentration of calcium ions in immune cells following stimulation with thymic peptides. <i>Cellular Immunology</i> , 2016, 302, 32-40.	1.4	6
16	A fragment of the alarmin prothymosin $\hat{\pm}$ as a novel biomarker in murine models of bacteria-induced sepsis. <i>Oncotarget</i> , 2017, 8, 48635-48649.	0.8	6
17	Study on the admission levels of circulating cell-free DNA in patients with acute myocardial infarction using different quantification methods. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2020, 80, 348-350.	0.6	3
18	A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer. <i>Anticancer Research</i> , 2016, 36, 3373-82.	0.5	3

#	ARTICLE	IF	CITATIONS
19	Synthesis and antiproliferative activity of some novel benzo-fused imidazo[1,8]naphthyridinones. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2621-2623.	1.0	2
20	Activation of the human natural killer cells NK-92 with a lymphocyte-derived cytokine-rich supernatant.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3108-3108.	0.8	1
21	Prothymosin α and Its C-Terminal Immunoreactive Decapeptide Show no Evidence of Acute Toxicity: A Preliminary in Silico, in Vitro and in Vivo Investigation. <i>Current Medicinal Chemistry</i> , 2021, 28, .	1.2	1
22	2nd Symposium on Advances in Cancer Immunology and Immunotherapy, December 15â€“17, 2016, Athens, Greece. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 153-159.	2.0	0
23	Immune responses induced by the TLR-4 agonist-based adjuvant prothymosin alpha.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11131-11131.	0.8	0